Bayer logo
US MEDICAL AFFAIRS

Publications

Contact Us icon

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiopulmonary diseases.

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated June, 2024.

Types of Enhancements Available

Infographic icon
Infographic
Video
Video

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 142    

Filtered results: 142

Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials

Rosenkranz S, et al. J Heart Lung Transplant. 2024:S1053-2498(24)01807-2

Rosenkranz S,
READ
EMAIL

How I Do It: A Collaborative, Interinstitutional Program to Improve the Care of Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Kelly BA, et al. CHEST Pulm. 2024;100092 Journal pre-proof

Kelly BA,
READ
EMAIL

Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis

Khanna D, et al. Rheumatology. 2024; Online ahead of print

Khanna D,
READ
EMAIL

Diagnosis and Treatment Patterns of Chronic Thromboembolic Pulmonary Hypertension in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia: A Registry Study

Öngen, HG, et al. Drugs - Real World Outcomes. 2024;11:149–165

Öngen,
READ
EMAIL

Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study

Benza RL , et al. JHLT. 2024;Online ahead of print

Benza RL,
READ
EMAIL

The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase

Benza EL, et al. ERR. 2024;33:230183

Benza RL,
READ
EMAIL

Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension

Caccamo M, et al. Pulm Circ. 2023;13(3):e12271

Caccamo M,
READ
EMAIL

Patient perspectives on pulmonary hypertension in the United States: Burdens, expectations, and goals

Braley K, et al. Pulm Circ. 2023;13(2):e12247

Braley K,
READ
EMAIL

Population pharmacokinetics of riociguat in a pediatric population (aged ≥6 years) with pulmonary arterial hypertension

Willmann S, et al. Pediatr Pulmonol. 2023;58(3):908-917

Willmann S,
READ
EMAIL

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial

Distler O, et al. Lancet Rheum. 2023;5(11):e660-e669

Distler O,
READ
EMAIL
Bayer logo

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2024 Bayer. Bayer and the Bayer Cross are registered trademarks for Bayer.

Site last updated 06/2024

Follow Us

Twitter (X) icon Twitter (X) icon
YouTube icon YouTube icon
LinkedIn icon LinkedIn icon
US Medical Affairs QR Code